Hans-Peter Holthoff Selected Research

Cyclic Peptides

1/2021	A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
1/2019	Therapeutic Effects of Short Cyclic and Combined Epitope Peptides in a Long-Term Model of Graves' Disease and Orbitopathy.
1/2018	Cyclopeptide COR-1 to treat beta1-adrenergic receptor antibody-induced heart failure.
1/2017	Cyclic Peptides for Effective Treatment in a Long-Term Model of Graves Disease and Orbitopathy in Female Mice.
11/2012	Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Peter Holthoff Research Topics

Disease

8	Graves Disease (Basedow Disease) 01/2021 - 08/2012
6	Tachycardia (Tachyarrhythmias) 01/2020 - 04/2015
3	Thrombosis (Thrombus) 01/2022 - 01/2013
3	Cardiomegaly (Heart Hypertrophy) 01/2018 - 04/2015
3	Heart Failure 01/2018 - 08/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2020
2	Hyperthyroidism 01/2020 - 01/2018
2	Fibrosis (Cirrhosis) 01/2019 - 01/2017
2	Cardiomyopathies (Cardiomyopathy) 01/2018 - 11/2012
2	Heart Diseases (Heart Disease) 01/2018 - 08/2012
2	Goiter 01/2017 - 04/2015
2	Stroke (Strokes) 01/2016 - 01/2013
2	Hemorrhage 01/2016 - 01/2013
2	Ischemic Stroke 01/2016 - 01/2013
2	Atherosclerosis 01/2013 - 03/2011
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 08/2012 - 04/2012
1	Infections 01/2022
1	Arthritis (Polyarthritis) 01/2021
1	Neoplasms (Cancer) 01/2020
1	Body Weight (Weight, Body) 01/2018
1	Hypertrophy 01/2017
1	Hypersensitivity (Allergy) 01/2017
1	Edema (Dropsy) 01/2013
1	Myocardial Infarction 01/2013
1	Cerebral Infarction 01/2013
1	Arteriosclerosis 06/2012
1	Atherosclerotic Plaque (Atheroma) 03/2011
1	Spontaneous Rupture 03/2011

Drug/Important Bio-Agent (IBA)

9	AntibodiesIBA 01/2020 - 04/2012
7	Thyrotropin Receptors (Thyrotropin Receptor)IBA 01/2021 - 04/2015
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2011
5	Cyclic PeptidesIBA 01/2021 - 11/2012
4	CollagenIBA 01/2021 - 03/2011
4	Peptides (Polypeptides)IBA 01/2021 - 08/2012
4	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2019 - 01/2017
3	EpitopesIBA 01/2019 - 08/2012
3	Glycoproteins (Glycoprotein)IBA 01/2016 - 01/2013
3	RevaceptIBA 01/2016 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2020
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2020
2	Long-Acting Thyroid Stimulator (LATS)IBA 01/2021 - 12/2020
2	Therapeutic UsesIBA 01/2019 - 01/2016
2	CholesterolIBA 01/2013 - 03/2011
1	VaccinesIBA 01/2022
1	Anti-Citrullinated Protein AntibodiesIBA 01/2021
1	acetyl 4-aminosalicylic acidIBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2021
1	Leucine (L-Leucine)FDA Link 01/2019
1	Immunoglobulin G (IgG)IBA 01/2017
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2013
1	AutoantibodiesIBA 08/2012
1	thyrotropin-binding inhibitory immunoglobulinIBA 08/2012
1	Member 1 Subfamily G ATP Binding Cassette TransporterIBA 06/2012
1	Apolipoproteins E (ApoE)IBA 03/2011
1	LDL Lipoproteins (beta Lipoproteins)IBA 03/2011
1	Carrier Proteins (Binding Protein)IBA 03/2011
1	oxidized low density lipoproteinIBA 03/2011

Therapy/Procedure

3	Therapeutics 01/2022 - 08/2012
2	Intravenous Administration 01/2021 - 01/2018
2	Injections 04/2017 - 01/2017
1	Drug Therapy (Chemotherapy) 01/2018
1	Thrombolytic Therapy 01/2016